FMC Corporation Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Q4 Sales:: $1.08 billion, down 11% year-over-year (5% decline on a like-for-like basis excluding India).

Adjusted EBITDA:: $280 million, a 17% decline year-over-year (8% decline on a like-for-like basis).

Adjusted EPS:: $1.20, down 33% due to lower EBITDA and higher interest expenses.

Free Cash Flow:: $623 million for Q4; however, 2025 free cash flow was negative $165 million.

Net Debt:: Approximately $3.5 billion, down over $550 million from Q3 2025, with a net debt to trailing twelve-month EBITDA ratio of 4.1 times.

2Strategic Updates and Business Highlights

FMC's board has authorized exploring strategic options, including a potential sale of the company, to enhance shareholder value.

Key operational priorities for 2026 include:

Paying down over $1 billion in debt through asset sales and licensing agreements.

Improving competitiveness of the core portfolio, particularly in managing the post-patent strategy for Rynaxypyr.

Driving growth from four new active ingredients, which saw sales increase from $130 million in 2024 to $200 million in 2025.

The company is in the process of selling its India commercial business, with binding bids expected in Q2 2026.

3Forward Guidance and Outlook

2026 Full-Year Sales Guidance:: Expected between $3.6 billion and $3.8 billion, down 5% at the midpoint compared to 2025.

Adjusted EBITDA Guidance:: Projected between $670 million and $730 million.

Q1 2026 Sales Guidance:: Anticipated between $725 million and $775 million, reflecting a 5% decline year-over-year.

New Active Ingredients Sales:: Expected to range from $300 million to $400 million in 2026, driven by registrations and market demand.

4Bad News, Challenges, or Points of Concern

Competitive Pressures:: Intense competition from generics, particularly affecting Rynaxypyr and the core portfolio, leading to pricing headwinds.

Declining Metrics:: Sales and EBITDA are expected to decline in 2026, primarily due to lower prices and volumes in the legacy portfolio.

Manufacturing Costs:: High-cost production facilities are limiting competitiveness, with plans to reduce costs by at least 35% by 2027, but this will require re-registration and inventory buildup.

Market Dynamics:: The introduction of generics is expected to increase resistance in pest populations, complicating sales strategies.

5Notable Q&A Insights

Strategic Review Process:: The decision to explore a sale was driven by a desire to maximize shareholder value and improve operational performance. Discussions are at an early stage, with financial and legal advisers retained.

Rynaxypyr Performance:: While branded Rynaxypyr earnings are expected to remain flat, partner sales are anticipated to decline due to pricing pressures and lower volumes.

Confidence in Growth:: Management expressed confidence in the growth of new active ingredients and the ability to stabilize the core portfolio, despite recent challenges.

Debt Management:: The company is focused on refinancing upcoming debt maturities and managing cash flows carefully to maintain compliance with covenants. Overall, FMC is navigating a challenging landscape with strategic initiatives aimed at improving financial health while exploring options for enhancing shareholder value.